Synopsis

Sickle Cell Disease Regional Care Excellence Program (SoRCE) is to improve the health of people with sickle cell disease (SCD) by expanding access to care, improving the quality of care, and tracking quality of life indicators. There are approximately 100,000 people in the United States with SCD. Treatment starting in early childhood can prevent or reduce complications such as severe pain episodes, silent strokes, and premature death. Despite universal identification at birth, fewer than half of children with SCD receive needed treatment. As these children become adolescents and transition to adulthood many are not appropriately identified as candidates for disease-modifying therapies, in part because their doctors are still learning how to use the latest treatments. The program is made up of seven regions with one award recipient per region serving as a Regional Coordinating Hub (RCH). Each award recipient will work with clinical and community-based partners in their region and engage in continuous quality improvement (CQI) initiatives to improve access and quality of care.
Response Date	Jul 08, 2026 12:00:00 AM EDT
Posting Date	Jun 05, 2026 12:00:00 AM EDT
Archive Date	Aug 30, 2026 12:00:00 AM EDT
Award Ceiling	950,000
Award Floor	N/a
Cost Sharing	No

Eligibility

Eligible Applicants	Public and State controlled institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Info on Eligibility:	Hospitals or clinicsHealth centers.

Additional Information

Agency Name	Health Resources and Services Administration
Link to Additional Information:	N/a
Grantor Contact Information:	If you have difficulty accessing the full announcement electronically, please contact: GrantSolutions Help Desk Phone: 301-443-7432

CFDA Program(s)

• 93.365: Sickle Cell Treatment Demonstration Program